A 16-year-old male is diagnosed with stage IV rhabdomyosarcoma with lung metastases. Molecular testing of the tumor is performed to help determine his prognosis and guide potential inclusion in clinical trials. Which of the following molecular findings is associated with the poorest prognosis in patients with metastatic rhabdomyosarcoma?